GM3 and cancer - PubMed

Review

GM3 and cancer

Sen-Itiroh Hakomori et al. Glycoconj J. 2015 Feb.

Abstract

Our studies during the early 1970s showed that expression of GM3, the simplest ganglioside and an abundant animal cell membrane component, is reduced during malignant transformation of cells by oncogenic viruses. Levels of mRNA for GM3 synthase were reduced in avian and mammalian cells transformed by oncoprotein "v-Jun", and overexpression of GM3 synthase in the transformed cells caused reversion from transformed to normal cell-like phenotype. GM3 has a well-documented inhibitory effect on activation of growth factor receptors (GFRs), particularly epidermal GFR (EGFR). De-N-acetyl GM3, which is expressed in some invasive human cancer cells, has an enhancing effect on EGFR activation. The important role of the sialosyl group of GM3 was demonstrated using NEU3, a plasma membrane-associated sialidase that selectively remove sialic acids from gangliosides GM3 and GD1a and is up-regulated in many human cancer cells. GM3 is highly enriched in a type of membrane microdomain termed "glycosynapse", and forms complexes with co-localized cell signaling molecules, including Src family kinases, certain tetraspanins (e.g., CD9, CD81, CD82), integrins, and GFRs (e.g., fibroblast growth factor receptor and hepatocyte growth factor receptor c-Met). Studies by our group and others indicate that GM3 modulates cell adhesion, growth, and motility by altering molecular organization in glycosynaptic microdomains and the activation levels of co-localized signaling molecules that are involved in cancer pathogenesis.

Similar articles

• A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9.

  Mitsuzuka K, Handa K, Satoh M, Arai Y, Hakomori S. Mitsuzuka K, et al. J Biol Chem. 2005 Oct 21;280(42):35545-53. doi: 10.1074/jbc.M505630200. Epub 2005 Aug 15. J Biol Chem. 2005. PMID: 16103120

• Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor.

  Toledo MS, Suzuki E, Handa K, Hakomori S. Toledo MS, et al. J Biol Chem. 2005 Apr 22;280(16):16227-34. doi: 10.1074/jbc.M413713200. Epub 2005 Feb 14. J Biol Chem. 2005. PMID: 15710618

• Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside).

  Miura Y, Kainuma M, Jiang H, Velasco H, Vogt PK, Hakomori S. Miura Y, et al. Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16204-9. doi: 10.1073/pnas.0407297101. Epub 2004 Nov 8. Proc Natl Acad Sci U S A. 2004. PMID: 15534203 Free PMC article.

• Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility.

  Hakomori SI. Hakomori SI. FEBS Lett. 2010 May 3;584(9):1901-6. doi: 10.1016/j.febslet.2009.10.065. Epub 2009 Oct 27. FEBS Lett. 2010. PMID: 19874824 Free PMC article. Review.

• Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains.

  Regina Todeschini A, Hakomori SI. Regina Todeschini A, et al. Biochim Biophys Acta. 2008 Mar;1780(3):421-33. doi: 10.1016/j.bbagen.2007.10.008. Epub 2007 Oct 22. Biochim Biophys Acta. 2008. PMID: 17991443 Free PMC article. Review.

Cited by

• GM130 regulates pulmonary surfactant protein secretion in alveolar type II cells.

  Pang Q, Liu C, Qiao Y, Zhao J, Lam SM, Mei M, Shui G, Bao S, Li Q. Pang Q, et al. Sci China Life Sci. 2022 Jan;65(1):193-205. doi: 10.1007/s11427-020-1875-x. Epub 2021 Mar 16. Sci China Life Sci. 2022. PMID: 33740186

• Role of glycosyltransferases in carcinogenesis; growth factor signaling and EMT/MET programs.

  Takahashi M, Hasegawa Y, Maeda K, Kitano M, Taniguchi N. Takahashi M, et al. Glycoconj J. 2022 Apr;39(2):167-176. doi: 10.1007/s10719-022-10041-3. Epub 2022 Jan 28. Glycoconj J. 2022. PMID: 35089466 Free PMC article. Review.

• Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance.

  Lee MY, Yeon A, Shahid M, Cho E, Sairam V, Figlin R, Kim KH, Kim J. Lee MY, et al. Oncotarget. 2018 Jan 13;9(17):13231-13243. doi: 10.18632/oncotarget.24229. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568353 Free PMC article.

• Attenuation of Bone Formation through a Decrease in Osteoblasts in Mutant Mice Lacking the GM2/GD2 Synthase Gene.

  Sasaki E, Hamamura K, Mishima Y, Furukawa K, Nagao M, Kato H, Hamajima K, Sato T, Miyazawa K, Goto S, Togari A. Sasaki E, et al. Int J Mol Sci. 2022 Aug 12;23(16):9044. doi: 10.3390/ijms23169044. Int J Mol Sci. 2022. PMID: 36012308 Free PMC article.

• Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.

  Jennemann R, Federico G, Mathow D, Rabionet M, Rampoldi F, Popovic ZV, Volz M, Hielscher T, Sandhoff R, Gröne HJ. Jennemann R, et al. Oncotarget. 2017 Nov 24;8(65):109201-109216. doi: 10.18632/oncotarget.22648. eCollection 2017 Dec 12. Oncotarget. 2017. PMID: 29312601 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal